ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SGP / news
ATEC (34) PRCT (38) AORT (40) BVS (61) ⌘ Pro Terminal →

Why SGP Stock surged +4.34% Today — RQD Quant Desk Flash

$33.64 +4.34% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $33.84

SpyGlass Pharma Inc. (SGP) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $1.08B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SGP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SGP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, SpyGlass Pharma Inc. (NASDAQ: SGP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $33.64 (+4.34% 1D, market cap $1.08B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SGP ranks #400 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SGP compare to ATEC and PRCT in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), SGP carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ATEC (Alphatec Holdings Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -18.4%, cap $1.09B) and PRCT (PROCEPT BioRobotics Corporation) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $1.10B). Among the 5-stock peer group, BVS leads on earnings multiple (55.0x) while BVS leads on capital efficiency (10.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SGP?
▼

Per SGP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001778922), SpyGlass Pharma Inc. generated $116.1M in revenue (+53.2% YoY), -$39.9M in net income, and -$33.5M in free cash flow against $115.9M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $33.84 (+0.59%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510043
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (7)Whales (15)SEC (10)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-6.7% Base Target
$37 Bull$31 Base$24 Bear
📬 FREE SGP RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SGP)Realized 20D OHLCV Swing Band: ±12.3%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY SGP SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (35% of score)

20D Institutional Volume Accumulation (±12.3% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
35
Grade E$23.92+9.4% Next Q
Q2 (-2Q)
38
Grade E$26.16+18.1% Next Q
Q3 (-1Q)
40
Grade D$30.90+8.9% Next Q
Current
43
Grade D-$33.64-6.7% Hist 90D α
Trajectory: E (35) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SGP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SGP currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($27.47) and Max Pain ($35.32) forces dealer call-delta covering toward $37.02.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SGP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SGP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 43%NO 57%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why SGP Stock surged +4.34% Today — RQD Quant Desk Flash

SpyGlass Pharma Inc. (SGP) surged +4.34% to $33.64, trading at 99% of its 52-week range ($17.06 – $33.84). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 99% of its 52-week range ($17.06 – $33.84) with RSI-14 at 70.2 (OVERBOUGHT (>70)).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.3% around $33.64 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live SGP Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SGP)

  • ✓Walkthrough of SGP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SGP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +37.81%⚡ TESTING RESISTANCE
2026-11-03O $32.51H $33.64L $32.24C $33.64VOL 94.2K
RES: $34.15SUP: $21.66SMA50: $27.47SMA200: $24.45
$35.01$30.15$25.28$20.42$15.55RES $34.15SUP $21.66$33.642026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SGP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SGP Butterfly Map → + Track SGP →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +53.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SGP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SGP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SGP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SGP)

Health Care Rank #400 of 1015 ⚔️ ATEC vs SGP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SGP vs. ATEC, PRCT, AORT, BVS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, SpyGlass Pharma Inc. (SGP) ranks #400 by composite RQD confidence (43/100, grade D-) and #347 by equity capitalization ($1.08B). Within this direct 5-issuer industry benchmark cohort, BVS leads on earnings valuation at 55.0x trailing P/E, while BVS leads on capital efficiency and profitability with 10.4% ROIC and 68.3% gross margin. BVS currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with SGP at 43/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SGP ACTIVE
SpyGlass Pharma Inc.
D- 43/100 — — -35.0% +4.34% $1.08B Benchmark Subject
ATEC
Alphatec Holdings Inc.
E 34/100 — 69.6% -18.4% +3.84% $1.09B /atec-vs-sgp →
PRCT
PROCEPT BioRobotics Corporation
D- 38/100 — 63.7% -35.0% +1.25% $1.10B /prct-vs-sgp →
AORT
Artivion Inc.
D- 40/100 117.0x 64.4% 4.5% +4.43% $1.10B /aort-vs-sgp →
BVS
Bioventus Inc. (Class A)
C- 61/100 55.0x 68.3% 10.4% -1.31% $1.12B /bvs-vs-sgp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001778922 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SpyGlass Pharma Inc. (SGP) reported GAAP revenue of $116.1M (+53.2% vs. FY2024 revenue of $75.8M ) , GAAP net income of -$39.9M, operating cash flow of -$32.7M, and free cash flow of -$33.5M (-39.4% YoY). On the balance sheet, SGP closed FY2025 with $115.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $116.1M -$39.9M -$32.7M -$33.5M $115.9M —
FY2024 (FY) 2024-12-31 $75.8M -$29.2M -$22.0M -$24.0M $23.3M —

3. SGP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SGP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, SpyGlass Pharma Inc. (NASDAQ: SGP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $33.64 (+4.34% 1D, market cap $1.08B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SGP ranks #400 in composite RQD confidence.

How does SGP compare to ATEC and PRCT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), SGP carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ATEC (Alphatec Holdings Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -18.4%, cap $1.09B) and PRCT (PROCEPT BioRobotics Corporation) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $1.10B). Among the 5-stock peer group, BVS leads on earnings multiple (55.0x) while BVS leads on capital efficiency (10.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SGP?

Per SGP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001778922), SpyGlass Pharma Inc. generated $116.1M in revenue (+53.2% YoY), -$39.9M in net income, and -$33.5M in free cash flow against $115.9M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SGP trading relative to its 50-day, 200-day, and 52-week technical levels?

SGP last traded at $33.64 (+4.34% on volume of 94,824 shares), positioning the stock +22.46% above its 50-day simple moving average ($27.47) and +37.59% above its 200-day simple moving average ($24.45). Across its 52-week range of $17.06 to $33.84, SGP sits at the 98.8% percentile with a 14-day RSI of 70.2 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.3% ($29.50 to $37.78).

Direct Sub-Reports: SGP RQD Cockpit SGP 12M Forecast SGP Earnings & Move SGP Dividends & DRIP SGP Insiders & 13F SGP Whale Options SGP Profit Sankey SGP News & Why
ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ SEC XBRL & RQD VERIFIED

SGP — SpyGlass Pharma Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

SpyGlass Pharma Inc. (SGP) earns a live Roarable RQD composite score of 43/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $33.64 (+4.34% 1D, market capitalization $1.08B).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -3.08%.
  • Whale 13F & Options Flow (15/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

SpyGlass Pharma Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry..1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), SpyGlass Pharma Inc. (SGP) reported $116.1M in annual revenue (up from $75.8M in FY2024, +53.2% YoY) and -$39.9M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($75.8M revenue, -$29.2M net income) through FY2025, SGP scaled operating cash flow to -$32.7M and free cash flow to -$33.5M, backed by $115.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 43/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -3.08% and institutional whale pillar of 15/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $17.06 – $33.84 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations beyond the Health Care sector and Medical/Dental Instruments industry classification.

  • Key Question #1: Can SGP sustain or expand its — operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $116.1M and free cash flow of -$33.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SGP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SGP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SpyGlass Pharma Inc. (SGP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SGP Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SGP Bull vs. Bear Conversation Board — What's Your Call at $33.64?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SGP 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SGP:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $41.91 (+30.0%)
📌 Pinned Debate

Cash rose from $16.3M to $96.4M between FY 2024 and FY 2025 while the stock sits near its 52-week high of $33.84.

Here is why I am bullish on SGP here at $32.24: Cash rose from $16.3M to $96.4M between FY 2024 and FY 2025 while the stock sits near its 52-week high of $33.84.. Compare SGP's 0.0% operating margin and -35.0% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $30.63 are getting bought.

SectorRotator 🐂 BULL

@ShortSeller_Dan Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $26.11 (-19.0%)
Spot @ $32.24

ROIC of -35%, FCF of -$33.5M in FY 2025, and a Piotroski F-Score of 2/9 point to continued cash consumption and weak forensic health.

Careful chasing SGP at $32.24. ROIC of -35%, FCF of -$33.5M in FY 2025, and a Piotroski F-Score of 2/9 point to continued cash consumption and weak forensic health.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $26.11 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%